Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jason Dowd"'
Publikováno v:
Biochemistry. 59(30)
The success of bevacizumab (Avastin), a monoclonal antibody (mAb) anticancer drug targeting vascular endothelial growth factor A (VEGF-A), has motivated the development of biosimilars. Establishing target epitope similarity using epitope mapping is a
Autor:
Amelia Cudd, Tudor Arvinte, Jason Dowd, Caroline Palais, Shanthi Rajendran, Stephen Brokx, Emilie Poirier
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 176
The physicochemical properties of Avastin® manufactured in the USA (Originator USA) and in Europe (Originator EU) and ABX-BEV, a bevacizumab biosimilar drug product candidate produced by Apobiologix Inc., were characterized at a clinically relevant
Autor:
Jason Dowd, Stephen Brokx, Amelia Cudd, Emilie Poirier, Shanthi Rajendran, Tudor Arvinte, Caroline Palais
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 175
The biosimilarity assessment of the physicochemical properties of high-concentration biopharmaceuticals is usually performed with measurements on diluted solutions, at concentrations below 1 mg/mL. In this study 13 orthogonal, spectroscopy and partic
Publikováno v:
Drug testing and analysis. 11(8)
The ongoing shift from small molecule drugs to protein therapeutics in the pharmaceuticals industry presents a considerable challenge to generic drug developers who are increasingly required to demonstrate biosimilarity for biological macromolecules,
Autor:
Kelly Miller, Nathaniel Lasry, Orad Reshef, Jason Dowd, Ives Araujo, Eric Mazur, Chandralekha Singh, Mel Sabella, Sanjay Rebello
Publikováno v:
AIP Conference Proceedings.
Researchers and practitioners routinely use the normalized gain (Hake, 1998) to evaluate the effectiveness of instruction. Normalized gain (g) has been useful in distinguishing active engagement from traditional instruction. Recently, concerns were r
Autor:
Kalpna Desai, Tina Catalano, Devanshi Maharaja, Jason Dowd, Louise Scrocchi, Stephen Brokx, Sanyukta Kher
Publikováno v:
Journal of Clinical Oncology. 33:e13534-e13534
e13528 Background: Biosimilar development involves extensive analytical testing to ensure comparability to the reference medicinal product to support the demonstration of similarity in terms of cli...
Autor:
Stephen Brokx, Kalpna Desai, Sanyukta Kher, Tina Catalano, Devanshi Maharaja, Louise Scrocchi, Jason Dowd
Publikováno v:
Journal of Clinical Oncology. 33:e13528-e13528
Autor:
Kalpna Desai, Jason Dowd, Grzegorz Orlik, Piotr Tomczak, Himanshu Gadgil, Agnieszka Jagiełło-Gruszfeld, Tina Catalano, Maria Skłodowska-Curie, Bernd Jilma
Publikováno v:
European Oncology & Haematology. 10:107
Aim: To demonstrate biosimilarity as evidenced by the pharmacokinetic (PK), pharmacodynamics (PD), efficacy and safety comparability of AccofilR/GrastofilR (filgrastim), a recombinant human granulocyte colony-stimulating factor, and the reference pro
Autor:
John Carvell, Jason Dowd
Publikováno v:
Cytotechnology; Mar2006, Vol. 50 Issue 1-3, p35-48, 14p